Amneal Pharmaceuticals (AMRX) announced that the U.S. Food and Drug Administration, FDA, has approved the Company’s albuterol sulfate inhalation aerosol. The product is the generic equivalent of PROAIR HFA, a registered trademark of Teva Respiratory. This approval follows the Company’s FDA approval of its beclomethasone dipropionate inhalation aerosol, a generic equivalent of QVAR, further advancing Amneal’s entry into complex inhaled and respiratory drug delivery. Together, these milestones underscore the Company’s momentum in building a differentiated, high-value respiratory portfolio supported by its state-of-the-art manufacturing platform.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise
- Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05%
- Amneal Pharmaceuticals announces FDA approval for iohexol injection
- Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges
- Amneal Pharmaceuticals price target raised to $13 from $11 at Piper Sandler